<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://oncologytube.com/videoEmbed/29060/kte-x19-study-safety-median-age-is-46-no-impact-seen-of-prior-blinatumomab-following-car-t-cell-therapy?channelName=AnnualCancerMeeting&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

KTE-X19 Study Safety: Median Age Is 46, No Impact Seen of Prior Blinatumomab Following CAR-T Cell Therapy

Name: KTE-X19 Study Safety: Median Age Is 46, No Impact Seen of Prior Blinatumomab Following CAR-T Cell Therapy
Uploaded: 2019-06-02T07:34:13
Duration: 1 min 7 s
Description: Bijal Shah MD Of Moffitt Cancer Center Discusses KTE-X19 Study Safety: Median Age Is 46, No Impact Seen of Prior Blinatumomab Following CAR-T Cell Therapy.

00:01:07

Annual Meeting

4 年 173 观看

分享添加到报告 0 0

嵌入 (Iframe):

<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://oncologytube.com/videoEmbed/29060/kte-x19-study-safety-median-age-is-46-no-impact-seen-of-prior-blinatumomab-following-car-t-cell-therapy?channelName=AnnualCancerMeeting&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

嵌入 (Object):

<div class="embed-responsive embed-responsive-16by9"><object width="640" height="360"><param name="movie" value="https://oncologytube.com/videoEmbed/29060/kte-x19-study-safety-median-age-is-46-no-impact-seen-of-prior-blinatumomab-following-car-t-cell-therapy?channelName=AnnualCancerMeeting&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit="></param><param name="allowFullScreen" value="true"></param><param name="allowscriptaccess" value="always"></param><embed src="https://oncologytube.com/videoEmbed/29060/kte-x19-study-safety-median-age-is-46-no-impact-seen-of-prior-blinatumomab-following-car-t-cell-therapy?channelName=AnnualCancerMeeting&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" allowscriptaccess="always" allowfullscreen="true" width="640" height="360"></embed></object></div>

链接 (HTML):

<a href="https://oncologytube.com/v/29060?channelName=AnnualCancerMeeting"><img src="https://oncologytubecom.cdn.ypt.me/videos/video_190602193413_d3bf/video_190602193413_d3bf.jpg?cache=15669162981682794628">KTE-X19 Study Safety: Median Age Is 46, No Impact Seen of Prior Blinatumomab Following CAR-T Cell Therapy</a>

链接 (BBCode):

[url=https://oncologytube.com/v/29060?channelName=AnnualCancerMeeting][img]https://oncologytubecom.cdn.ypt.me/videos/video_190602193413_d3bf/video_190602193413_d3bf.jpg?cache=15669162981682794628[/img]KTE-X19 Study Safety: Median Age Is 46, No Impact Seen of Prior Blinatumomab Following CAR-T Cell Therapy[/url]

立即登录!

永久链接

友好网址 (SEO)

当前时间 (SEO)

分类:

Acute Lymphoblastic Leukemia

描述:

Bijal Shah MD Of Moffitt Cancer Center Discusses KTE-X19 Study Safety: Median Age Is 46, No Impact Seen of Prior Blinatumomab Following CAR-T Cell Therapy.